From the nervous system: peripheral neuropathy as a mild to moderate paresthesia, hyperesthesia, dysesthesia or pain including burning. Movement trenbolone disorders characterized by weakness. In case of these symptoms require dose adjustment. If symptoms persist, treatment should be discontinued. Rarely observed the development of seizures, and transient loss of consciousness.

Cardio-vascular system: cardiac arrhythmia (sinus tachycardia, atrial fibrillation), heart failure, high or low blood pressure. Occasionally there have been cases of venous thromboembolism and myocardial infarction.

From the hepato-biliary system: in patients receiving Taxotere monotherapy at a dose of 100 mg / m 2 , increased serum activity , and alkaline phosphatase concentration in serum bilirubin more than 2.5 times the upper limit of normal, says less than 5%. Very rarely there have been cases of hepatitis (fatal outcome was observed in patients with liver disease in history).

From the respiratory system: very rarely – acute respiratory distress syndrome, interstitial pneumonia, pulmonary fibrosis and increased reaction to radiation.

From the Musculoskeletal System: arthralgia, myalgia, muscle weakness. On the part of the organs of vision: rarely – the development tearing combined with conjunctivitis (or without it), transient visual disturbances (flashes of light in the eyes, the appearance of cattle), usually occurring during injection and development combined with hypersensitivity reactions, which usually disappear after cessation of infusion; very rarely, mainly in patients receiving the combination of other antineoplastic agents may develop occlusion of the tear duct, resulting in excessive tearing.

Reactions at the injection site : moderately trenbolone expressed and manifested in the form of hyperpigmentation, inflammation, redness or dryness of the skin, phlebitis, hemorrhage or venous edema. Other: fatigue, shortness of breath, generalized or local pain, including chest pain, non-cardiac diseases and lungs. When using docetaxel (Taxotere) in combination with capecitabine is observed more frequent adverse events from the gastrointestinal tract, hand-jog syndrome (limb skin redness (hands and feet), followed by swelling and desquamation), dehydration, watery eyes, arthralgia, heavy thrombocytopenia and anemia, hyperbilirubinemia, but more rare development of severe neutropenia, alopecia, violations of the nails, fatigue, myalgia, edema of the lower extremities. Patients 60 years and older who received combination therapy with capecitabine and Taxotere, compared with younger patients, more frequent development toxicity grade 3-4.

Patients receiving combination treatment trenbolone and trastuzumab was found a higher rate of side effects and more frequent development toxicity grade 4, compared  monotherapy. cases of heart failure were identified, especially in addition to therapy with anthracyclines (doxorubicin or epirubicin).

When using docetaxel  in combination with cisplatin  febrile neutropenia and / or neutropenic infection complications arise in the smaller percentage of cases when administered .